ANTI-FXR1 CLONE 1L9 ZOOMAB« RABBIT MONOCLONAL (C005B-260637)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1L9 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects RNA-binding protein FXR1. It targets an epitope within 25 amino acids from the C-terminal region.

Immunogen

KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal region of human RNA-binding protein FXR1.

Application

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected FXR1 in HeLa cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected FXR1 in HepG2 cell lysate and 1:10,000 dilution in Human brain tissue lysate.

Affinity Binding Assay: A representative lot of this antibody bound FXR1 peptide with a KD of 1.1 x 10-6 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected FXR1 in HepG2 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected FXR1 in human cerebral cortex tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

RNA-binding protein FXR1 (UniProt: P51114; also known as FMR1 autosomal homolog 1, hFXR1p) is encoded by the FXR1 gene (Gene ID: 8087) in human. FXR1 is a cytoplasmic protein that is expressed in all tissues examined. It contains RNA-binding domains that are localized in amino acids 222-251 (KH1); 285-314 (KH2) and 442-457 (RNA-binding RGG-box ) and differentially regulate RNA translation and stability. It is required for embryonic and postnatal development of muscle tissue. Three isoforms of FXR1 have been described that are produced by alternative splicing. The isoform balance is reported to be altered in myotonic dystrophy, facioscapulohumeral muscular dystrophy, and in diabetes. It is a muscle-enhanced and IL-19- inducible RNA-binding protein that acts as a negative regulator of inflammatory gene expression by competing with HuR on the 30 UTR of inflammatory mRNA transcripts. It is required for IL-19-dependent reduction of HuR mRNA stability and abundance. FXR1 are also shown to form amyloid oligomers and insoluble aggregates in rat cortical neurons and these amyloid conformers are resistant to RNase treatment.  In its monomeric form,  FXR1 are almost undetectable. FXR1 depletion is shown to be perinatally lethal in mice, Xenopus, and zebrafish.  This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Smith, JA., et al. (2020). J. Cell Biol. 219(4); e201911129; Sopova, JV., et al. (2019). Sci. Rep. 9; Article 18983; Herman, AB., et al. (2018). Cell Rep. 24(5); 1176-1189).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.